U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C46H73N4O9
Molecular Weight 826.0932
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of Minopafant ion

SMILES

CCCCCCCCCCCCCCCCCCNC(=O)OC1CCN(CC1)C(=O)OC[C@H](COC(=O)N(CC2=CC=CC=[N+]2CC)C(=O)C3=CC=CC=C3OC)OC

InChI

InChIKey=HGOAIWZFTWACBD-RRHRGVEJSA-O
InChI=1S/C46H72N4O9/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-19-20-24-31-47-44(52)59-39-29-33-49(34-30-39)45(53)57-36-40(55-3)37-58-46(54)50(35-38-26-23-25-32-48(38)6-2)43(51)41-27-21-22-28-42(41)56-4/h21-23,25-28,32,39-40H,5-20,24,29-31,33-37H2,1-4H3/p+1/t40-/m1/s1

HIDE SMILES / InChI
Molecular Formula C46H73N4O9
Molecular Weight 826.0932
Charge 1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Minopafant (E5880) is a novel platelet activating factor receptor antagonist. Minopafant had been in phase II clinical trials by Eisai in Japan for the treatment of disseminated intravascular coagulation. However, this research has been discontinued.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 0.27 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1132
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Effect of a platelet-activating factor receptor antagonist, E5880, on cerebral vasospasm after aneurysmal subarachnoid hemorrhage--open clinical trial to investigate efficacy and safety.
2001 Apr
Patents

Patents

US20150147276
2

Sample Use Guides

In Vivo Use Guide
Intravenous Minopafant administration (300 ug or 1200 ug twice daily) was begun within 4 days and continued for 14 days.
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment: The cultured neurons were exposed to glutamate (1 mM) for 60 min. Twenty-four hours after this exposure, protective effect of E5880 against neuronal damage was tested.
Minopafant (E5880) was tested for its neuroprotective activity in primary neuronal cultures isolated from embryonic rat cerebral cortex. Protective effect was observed in cultures treated with E5880 (P < 0.01 at 10 nM E5880)
Substance Class Chemical
Created
by admin
on Sat Dec 16 19:34:35 UTC 2023
Edited
by admin
on Sat Dec 16 19:34:35 UTC 2023
Record UNII
R382T79GF8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Minopafant ion
Common Name English
Pyridinium, 1-ethyl-2-[[(2-methoxybenzoyl)[[(2R)-2-methoxy-3-[[[4-[[(octadecylamino)carbonyl]oxy]-1-piperidinyl]carbonyl]oxy]propoxy]carbonyl]amino]methyl]-
Systematic Name English
Minopafant cation
Common Name English
1-Ethyl-2-[[(2-methoxybenzoyl)[[(2R)-2-methoxy-3-[[[4-[[(octadecylamino)carbonyl]oxy]-1-piperidinyl]carbonyl]oxy]propoxy]carbonyl]amino]methyl]pyridinium
Systematic Name English
Code System Code Type Description
PUBCHEM
130991
Created by admin on Sat Dec 16 19:34:35 UTC 2023 , Edited by admin on Sat Dec 16 19:34:35 UTC 2023
PRIMARY
FDA UNII
R382T79GF8
Created by admin on Sat Dec 16 19:34:35 UTC 2023 , Edited by admin on Sat Dec 16 19:34:35 UTC 2023
PRIMARY
CAS
760911-49-7
Created by admin on Sat Dec 16 19:34:35 UTC 2023 , Edited by admin on Sat Dec 16 19:34:35 UTC 2023
PRIMARY
Related Record Type Details
Structure of Minopafant
SALT/SOLVATE -> PARENT
PLATELET-ACTIVATING FACTOR RECEPTOR
TARGET -> INHIBITOR
Structure of Minopafant ion
IONIC MOIETY
Related Record Type Details
Structure of Minopafant ion
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966